Investigators
Basic Information
-
Investigator
- Ai-Young Lee
-
Country
- South Korea
-
Affiliation
- Dongguk University Ilsan Hospital
-
Specialty
- Dermatology
Clinical Trial History
-
Clinical Trial Experience
- 2 year
-
Multicenter Clinical Trial Performance Status
- Yes
-
IND Submission History (Count)
- 0 Count
-
Related Papers/Publications (Count)
- 18 Count
Clinical Trial Details
Total 5
-
Trial Title
-
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis (BREEZE-AD3)
-
Therapy Area
- Dermatology
-
Indication(s)
- Atopic Dermatitis (Atopic Eczema)
-
Investigator’s Role
- Contact Person; Principal Investigator
-
Trial Phase
- Phase III
-
Trial Status
- Completed
-
Trial Title
-
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis (BREEZE-AD3)
-
Therapy Area
- Dermatology
-
Indication(s)
- Dermatitis (Eczema)
-
Investigator’s Role
- Contact Person; Principal Investigator
-
Trial Phase
- Phase III
-
Trial Status
- Completed
-
Trial Title
-
A Study to Help Understand How Baricitinib in Combination with Topical Corticosteroids Compares to Placebo (a Tablet That Does Not Contain Any Active Medicine) in Patients with Moderate to Severe Atopic Dermatitis, Also Named Atopic
-
Therapy Area
- Dermatology
-
Indication(s)
- Atopic Dermatitis (Atopic Eczema)
-
Investigator’s Role
- Contact Person; Principal Investigator
-
Trial Phase
- Phase III
-
Trial Status
- Completed
-
Trial Title
-
Safety and Efficacy of FURESTEM-AD Inj. in Patients with Moderate to Severe Chronic Atopic Dermatitis (AD)
-
Therapy Area
- Dermatology
-
Indication(s)
- Atopic Dermatitis (Atopic Eczema)
-
Investigator’s Role
- Contact Person; Principal Investigator
-
Trial Phase
- Phase III
-
Trial Status
- Completed
-
Trial Title
-
A Pilot Study to Evalaute the Efficacy of Combination of Glucosamine Improved Therapeutic Effect of Low-dose Cyclosporin a in Subjects with Atopic Dermatitis
-
Therapy Area
- Dermatology
-
Indication(s)
- Atopic Dermatitis (Atopic Eczema)
-
Investigator’s Role
- Co-Author
-
Trial Phase
- Phase II
-
Trial Status
- Completed